Overview

CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects

Status:
Unknown status
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
To explore the effect on early viral kinetics and viral load, and to determine safety, tolerability and anti-viral response for the plasmid DNA vaccine CHRONVAC-C administered i.m. in combination with electroporation followed by standard of care (SOC) in treatment naïve chronic HCV genotype 1 patients.
Phase:
Phase 2
Details
Lead Sponsor:
ChronTech Pharma AB
Collaborator:
Inovio Pharmaceuticals